192 related articles for article (PubMed ID: 15667916)
1. Polyomavirus SV40 infections in Kazakhstan.
Nurgalieva ZZ; Wong C; Zhangabylov AK; Omarbekova ZE; Graham DY; Vilchez RA; Butel JS
J Infect; 2005 Feb; 50(2):142-8. PubMed ID: 15667916
[TBL] [Abstract][Full Text] [Related]
2. Population-based study of antibody to the human polyomaviruses BKV and JCV and the simian polyomavirus SV40.
Knowles WA; Pipkin P; Andrews N; Vyse A; Minor P; Brown DW; Miller E
J Med Virol; 2003 Sep; 71(1):115-23. PubMed ID: 12858417
[TBL] [Abstract][Full Text] [Related]
3. Serological evidence of SV40 infections in HIV-infected and HIV-negative adults.
Jafar S; Rodriguez-Barradas M; Graham DY; Butel JS
J Med Virol; 1998 Apr; 54(4):276-84. PubMed ID: 9557293
[TBL] [Abstract][Full Text] [Related]
4. Case-control study of simian virus 40 and non-Hodgkin lymphoma in the United States.
Engels EA; Viscidi RP; Galloway DA; Carter JJ; Cerhan JR; Davis S; Cozen W; Severson RK; de Sanjose S; Colt JS; Hartge P
J Natl Cancer Inst; 2004 Sep; 96(18):1368-74. PubMed ID: 15367569
[TBL] [Abstract][Full Text] [Related]
5. High prevalence of SV40 infection in patients with nodal non-Hodgkin's lymphoma but not acute leukemia independent of contaminated polio vaccines in Taiwan.
Chen PM; Yen CC; Yang MH; Poh SB; Hsiao LT; Wang WS; Lin PC; Lee MY; Teng HW; Bai LY; Chu CJ; Chao SC; Yang AH; Chiou TJ; Liu JH; Chao TC
Cancer Invest; 2006; 24(3):223-8. PubMed ID: 16809147
[TBL] [Abstract][Full Text] [Related]
6. Is there a role for SV40 in human cancer?
Poulin DL; DeCaprio JA
J Clin Oncol; 2006 Sep; 24(26):4356-65. PubMed ID: 16963733
[TBL] [Abstract][Full Text] [Related]
7. Simian virus 40 (SV40) and human cancer: a review of the serological data.
Shah KV; Galloway DA; Knowles WA; Viscidi RP
Rev Med Virol; 2004; 14(4):231-9. PubMed ID: 15248251
[TBL] [Abstract][Full Text] [Related]
8. Childhood exposure to simian virus 40-contaminated poliovirus vaccine and risk of AIDS-associated non-Hodgkin's lymphoma.
Engels EA; Rodman LH; Frisch M; Goedert JJ; Biggar RJ
Int J Cancer; 2003 Aug; 106(2):283-7. PubMed ID: 12800207
[TBL] [Abstract][Full Text] [Related]
9. SV40, genetic polymorphism and mesothelioma. pathological and epidemiological evidence.
Magnani C
Med Lav; 2005; 96(4):347-53. PubMed ID: 16457431
[TBL] [Abstract][Full Text] [Related]
10. Lack of serologic evidence for prevalent simian virus 40 infection in humans.
Carter JJ; Madeleine MM; Wipf GC; Garcea RL; Pipkin PA; Minor PD; Galloway DA
J Natl Cancer Inst; 2003 Oct; 95(20):1522-30. PubMed ID: 14559874
[TBL] [Abstract][Full Text] [Related]
11. Antibody responses to simian virus 40 T antigen: a case-control study of non-Hodgkin lymphoma.
Engels EA; Chen J; Hartge P; Cerhan JR; Davis S; Severson RK; Cozen W; Viscidi RP
Cancer Epidemiol Biomarkers Prev; 2005 Feb; 14(2):521-4. PubMed ID: 15734981
[TBL] [Abstract][Full Text] [Related]
12. Review of prevalence of Simian Virus 40 (SV40) genomic infection in healthy subjects.
Paracchini V; Garte S; Pedotti P; Taioli E
Mutat Res; 2006 Mar; 612(2):77-83. PubMed ID: 16081314
[TBL] [Abstract][Full Text] [Related]
13. Ethnic differences in polyomavirus simian virus 40 seroprevalence among women in Houston, Texas.
Wong C; Vilchez RA; Quiroz J; Adam E; Butel JS
J Infect; 2013 Jan; 66(1):67-74. PubMed ID: 22940252
[TBL] [Abstract][Full Text] [Related]
14. Poliovirus vaccination during pregnancy, maternal seroconversion to simian virus 40, and risk of childhood cancer.
Engels EA; Chen J; Viscidi RP; Shah KV; Daniel RW; Chatterjee N; Klebanoff MA
Am J Epidemiol; 2004 Aug; 160(4):306-16. PubMed ID: 15286015
[TBL] [Abstract][Full Text] [Related]
15. Public health. Creeping consensus on SV40 and polio vaccine.
Ferber D
Science; 2002 Oct; 298(5594):725-7. PubMed ID: 12399560
[No Abstract] [Full Text] [Related]
16. Simian virus 40 sequences in blood specimens from healthy individuals of Casale Monferrato, an industrial town with a history of asbestos pollution.
Pancaldi C; Balatti V; Guaschino R; Vaniglia F; Corallini A; Martini F; Mutti L; Tognon M
J Infect; 2009 Jan; 58(1):53-60. PubMed ID: 19070904
[TBL] [Abstract][Full Text] [Related]
17. SV40 seroprevalence in two Latin American countries involved in field trials of candidate oral poliovaccines.
Wong C; Zhang S; Adam E; Paszat L; Butel JS
J Infect; 2019 Jun; 78(6):476-483. PubMed ID: 30965068
[TBL] [Abstract][Full Text] [Related]
18. An investigation of the occurrence of SV40 antibodies in South Africa.
Basetse HR; Lecatsas G; Gerber LJ
S Afr Med J; 2002 Oct; 92(10):825-8. PubMed ID: 12432810
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of SV40 in osteosarcoma and healthy population: a Hungarian-German study.
Heinsohn S; Szendroi M; Bielack S; Stadt UZ; Kabisch H
Oncol Rep; 2009 Feb; 21(2):289-97. PubMed ID: 19148498
[TBL] [Abstract][Full Text] [Related]
20. Potential exposure to SV40 in polio vaccines used in Sweden during 1957: no impact on cancer incidence rates 1960 to 1993.
Olin P; Giesecke J
Dev Biol Stand; 1998; 94():227-33. PubMed ID: 9776244
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
